Top

Published in:

01-07-2014 | MOVEMENT DISORDERS (O SUCHOWERSKY, SECTION EDITOR)

Therapies for Ataxias

Authors: Laurence Martineau, MD, Anne Noreau, MSc, Nicolas Dupré, MD, MSc, FRCP(C)

Published in: Current Treatment Options in Neurology | Issue 7/2014

Opinion statement

Ataxia can originate from many genetic defects, but also from nongenetic causes. To be able to provide treatment, the first step is to establish the right diagnosis. Once the cause of the ataxia is defined, some specific treatments may be available. For example, the nongenetic ataxias that arise from vitamin deficiencies can improve following treatment. In most cases, however, therapies do not cure the disease and are purely symptomatic. Physiotherapy and occupational therapy are effective in all type of ataxias and often remain the most efficient treatment option for these patients to maximize their quality of life.

1.•

Jayadev S, Bird TD. Hereditary ataxias: overview. Genet Med. 2013;15:673–83.PubMed

2.••

van de Warrenburg BP, van Gaalen J, Boesch S, Burgunder JM, Durr A, Giunti P, et al. EFNS/ENS consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol. 2014;21:552–62.PubMed

3.•

Marquer A, Barbieri G, Perennou D. The assessment and treatment of postural disorders in cerebellar ataxia: a systematic review. Ann Phys Rehabil Med. 2014;57:67–78.PubMed

Miyai I. Challenge of neurorehabilitation for cerebellar degenerative diseases. Cerebellum. 2012;11:436–7.PubMed

Ilg W, Schatton C, Schicks J, Giese MA, Schols L, Synofzik M. Video game-based coordinative training improves ataxia in children with degenerative ataxia. Neurology. 2012;79:2056–60.PubMed

Saute JA, de Castilhos RM, Monte TL, Schumacher-Schuh AF, Donis KC, D'Avila R, et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord. 2014;29:568–73.PubMed

Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007;4:e182.PubMedCentralPubMed

Jia DD, Zhang L, Chen Z, Wang CR, Huang FZ, Duan RH, et al. Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3beta in a SCA3 Drosophila model. Cerebellum. 2013;12:892–901.PubMed

Ulatowski L, Parker R, Warrier G, Sultana R, Butterfield DA, Manor D. Vitamin E is essential for Purkinje neuron integrity. Neuroscience. 2014;260:120–9.PubMed

10.

Ouahchi K, Arita M, Kayden H, Hentati F, Ben Hamida M, Sokol R, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet. 1995;9:141–5.PubMed

11.

Di Donato I, Bianchi S, Federico A. Ataxia with vitamin E deficiency: update of molecular diagnosis. Neurol Sci. 2010;31:511–5.PubMed

12.

Schuelke M, Mayatepek E, Inter M, Becker M, Pfeiffer E, Speer A, et al. Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. J Pediatr. 1999;134:240–4.PubMed

13.

Sokol RJ, Guggenheim MA, Iannaccone ST, Barkhaus PE, Miller C, Silverman A, et al. Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med. 1985;313:1580–6.PubMed

14.

Khatun I, Walsh MT, Hussain MM. Loss of both phospholipid and triglyceride transfer activities of microsomal triglyceride transfer protein in abetalipoproteinemia. J Lipid Res. 2013;54:1541–9.PubMedCentralPubMed

15.

Hammer MB, El Euch-Fayache G, Nehdi H, Feki M, Maamouri-Hicheri W, Hentati F, et al. Clinical features and molecular genetics of two Tunisian families with abetalipoproteinemia. J Clin Neurosci. 2014;21:311–5.PubMed

16.

Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis. 2014;37(3):333–9.

17.

Frydman M, Bonne-Tamir B, Farrer LA, Conneally PM, Magazanik A, Ashbel S, et al. Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus. Proc Natl Acad Sci U S A. 1985;82:1819–21.PubMedCentralPubMed

18.

European Association for Study of EASL Clinical Practice Guidelines. Wilson's disease. J Hepatol. 2012;56:671–85.

19.

Lorincz MT. Neurologic Wilson's disease. Ann N Y Acad Sci. 2010;1184:173–87.PubMed

20.

Weiss KH, Stremmel W. Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring. Curr Gastroenterol Rep. 2012;14:1–7.PubMed

21.

Lorincz MT. Recognition and treatment of neurologic Wilson's disease. Semin Neurol. 2012;32:538–43.PubMed

22.

Weiss LH, Thurik F, Gotthardt DN, Schafer M, Teufel U, Wiegand F, et al. Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11:1028–35. e1021‒2.PubMed

23.

Kim B, Chung SJ, Shin HW. Trientine-induced neurological deterioration in a patient with Wilson's disease. J Clin Neurosci. 2013;20:606–8.PubMed

24.

Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs. 2009;18:89–97.PubMed

25.

Czlonkowska A, Litwin T, Karlinski M, Dziezyc K, Chabik G, Czerska M. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease. Eur J Neurol. 2014;21:599–606.PubMed

26.

Reynolds HV, Talekar CR, Bellapart J, Leggett BA, Boots RJ. Copper removal strategies for Wilson's disease crisis in the ICU. Anaesth Intensive Care. 2014;42:253–7.PubMed

27.

Guillaud O, Dumortier J, Sobesky R, Debray D, Wolf P, Vanlemmens C, et al. Long-term results of liver transplantation for Wilson's disease: experience in France. J Hepatol. 2014;60:579–89.PubMed

28.

Merle U, Stremmel W, Encke J. Perspectives for gene therapy of Wilson disease. Curr Gene Ther. 2007;7:217–20.PubMed

29.

Mihalik SJ, Morrell JC, Kim D, Sacksteder KA, Watkins PA, Gould SJ. Identification of PAHX, a Refsum disease gene. Nat Genet. 1997;17:185–9.PubMed

30.

van den Brink DM, Brites P, Haasjes J, Wierzbicki AS, Mitchell J, Lambert-Hamill M, et al. Identification of PEX7 as the second gene involved in Refsum disease. Am J Hum Genet. 2003;72:471–7.PubMedCentralPubMed

31.

Wierzbicki AS, Lloyd MD, Schofield CJ, Feher MD, Gibberd FB. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J Neurochem. 2002;80:727–35.PubMed

32.

Wierzbicki AS, Mitchell J, Lambert-Hammill M, Hancock M, Greenwood J, Sidey MC, et al. Identification of genetic heterogeneity in Refsum's disease. Eur J Hum Genet. 2000;8:649–51.PubMed

33.

Baldwin EJ, Gibberd FB, Harley C, Sidey MC, Feher MD, Wierzbicki AS. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry. 2010;81:954–7.PubMed

34.

Hungerbuhler JP, Meier C, Rousselle L, Quadri P, Bogousslavsky J. Refsum's disease: management by diet and plasmapheresis. Eur Neurol. 1985;24:153–9.PubMed

35.

Zolotov D, Wagner S, Kalb K, Bunia J, Heibges A, Klingel. Long-term strategies for the treatment of Refsum's disease using therapeutic apheresis. J Clin Apher. 2012;27:99–105.PubMed

36.

Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011;303:1–12.PubMedCentralPubMed

37.

Gomes CM, Santos R. Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress. Oxidative Med Cell Longev. 2013;2013:487534.

38.

Isaya G. Mitochondrial iron-sulfur cluster dysfunction in neurodegenerative disease. Front Pharmacol. 2014;5:29.PubMedCentralPubMed

39.

Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J Neurochem. 2013;126 Suppl 1:103–17.PubMed

40.

Payne RM, Wagner GR. Cardiomyopathy in Friedreich ataxia: clinical findings and research. J Child Neurol. 2012;27:1179–86.PubMedCentralPubMed

41.

Salih MA, Ahlsten G, Stalberg E, Schmidt R, Sunnegardh J, Michaelsson M, et al. Friedreich's ataxia in 13 children: presentation and evolution with neurophysiologic, electrocardiographic, and echocardiographic features. J Child Neurol. 1990;5:321–6.PubMed

42.

Perlman SL. A review of Friedreich ataxia clinical trial results. J Child Neurol. 2012;27:1217–22.PubMed

43.

Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich's ataxia. J Neurochem. 2013;126 Suppl 1:142–6.PubMed

44.

Velasco-Sanchez D, Aracil A, Montero R, Mas A, Jimenez L, O'Callaghan M, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum. 2011;10:1–8.PubMed

45.

Schols L, Zange J, Abele M, Schillings M, Skipka G, Kuntz-Hehner S, et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm. 2005;112:789–96.PubMed

46.

Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15:1371–9.PubMed

47.

Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley FG, Turner C, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005;62:621–6.PubMed

48.

Soragni E, Xu C, Plasterer HL, Jacques V, Rusche JR, Gottesfeld JM. Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J Child Neurol. 2012;27:1164–73.PubMedCentralPubMed

49.

Gottesfeld JM, Rusche JR, Pandolfo M. Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia. J Neurochem. 2013;126 Suppl 1:147–54.PubMedCentralPubMed

50.

Marmolino D, Acquaviva F. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy. Cerebellum. 2009;8:245–59.PubMed

51.

Nachbauer W, Boesch S, Schneider R, Eigentler A, Wanschitz J, Poewe W, et al. Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin. PLoS One. 2013;8:e69229.PubMedCentralPubMed

52.

Mariotti C, Nachbauer W, Panzeri M, Poewe W, Taroni F, Boesch S. Erythropoietin in Friedreich ataxia. J Neurochem. 2013;126 Suppl 1:80–7.PubMed

53.

Richardson TE, Kelly HN, Yu AE, Simpkins JW. Therapeutic strategies in Friedreich's ataxia. Brain Res. 2013;1514:91–7.PubMed

54.

Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci. 2006;27:143–9.PubMed

55.

Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med. 2004;27:42–50.PubMed

56.

Arlazoroff A, Roitberg B, Werber E, Shidlo R, Berginer VM. Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia. 1991;32:657–61.PubMed

57.

Grandas F, Martin-Moro M, Garcia-Munozguren S, Anaya F. Early-onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord. 2002;17:1396–7.PubMed

58.

Alcalay R, Wu S, Patel S, Frucht S. Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis. Mov Disord. 2009;24:1397–9.PubMed

59.

Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18:1203–11.PubMed

60.

Chen SF, Tsai NW, Chang SS, Lu CH, Huang CR, Chuang YC, et al. Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. BMC Neurol. 2011;11:63.PubMedCentralPubMed

61.

Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology. 2009;72:750–9.PubMedCentralPubMed

62.

Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984;311:1649–52.PubMed

63.

Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol. 2013;36:78–83.PubMed

64.

Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988;336:577–80.PubMed

65.

Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53.PubMed

66.

Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med. 1992;82:169–79.PubMed

67.

Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003;10:173–82.PubMed

68.

Verhagen MM, Abdo WF, Willemsen MA, Hogervorst FB, Smeets DF, Hiel JA, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology. 2009;73:430–7.PubMed

69.

Zannolli R, Buoni S, Betti G, Salvucci S, Plebani A, Soresina A, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord. 2012;27:1312–6.PubMed

70.

Broccoletti T, Del Giudice E, Cirillo E, Vigliano I, Giardino G, Ginocchio VM, et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol. 2011;18:564–70.PubMed

71.

Giardino G, Fusco A, Romano R, Gallo V, Maio F, Esposito T, et al. Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis. Eur J Neurol. 2013;20:740–7.PubMed

72.

Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull. 2007;81–82:129–47.PubMed

73.

Spiegel R, Raas-Rothschild A, Reish O, Regev M, Meiner V, Bargal R, et al. The clinical spectrum of fetal Niemann-Pick type C. Am J Med Genet A. 2009;149A:446–50.PubMed

74.

Vanier MT. Phenotypic and genetic heterogeneity in Niemann-Pick disease type C: current knowledge and practical implications. Wien Klin Wochenschr. 1997;109:68–73.PubMed

75.

Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.PubMedCentralPubMed

76.

Mengel E, Klunemann HH, Lourenco CM, Hendriksz CJ, Sedel F, Walterfang M, et al. Niemann-Pick disease type C symptomatology: an expert-based clinical description. Orphanet J Rare Dis. 2013;8:166.PubMedCentralPubMed

77.

Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, Vanier MT, et al. The adult form of Niemann-Pick disease type C. Brain. 2007;130:120–33.PubMed

78.

Anheim M, Lagha-Boukbiza O, Fleury-Lesaunier MC, Valenti-Hirsch MP, Hirsch E, Gervais-Bernard H, et al. Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease. J Neurol. 2014;261:174–9.PubMed

79.

Lyseng-Williamson KA. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs. 2014;74:61–74.PubMed

80.

Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F. NP-C Guidelines Working Group. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;106:330–44.

81.

Maceyka M, Milstien S, Spiegel S. The potential of histone deacetylase inhibitors in Niemann - Pick type C disease. FEBS J. 2013;280:6367–72.PubMed

82.

Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW. CINCH investigators. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain. 2007;130:2484–93.

83.

Eunson LH, Rea R, Zuberi SM, Youroukos S, Panayiotopoulos CP, Liguori R, et al. Spauschus. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol. 2000;48:647–56.PubMed

84.

Graves TD, Cha YH, Hahn AF, Barohn R, Salajegheh MK, Griggs RC, et al. CINCH investigators Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain. 2014;137:1009–18.

85.

Browne DL, Gancher ST, Nutt JG, Brunt ER, Smith EA, Kramer P, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet. 1994;8:136–40.PubMed

86.

Spacey SD, Hildebrand ME, Materek LA, Bird TD, Snutch TP. Functional implications of a novel EA2 mutation in the P/Q-type calcium channel. Ann Neurol. 2004;56:213–20.PubMed

87.

Jen J. Familial episodic ataxias and related ion channel disorders. Curr Treat Options Neurol. 2000;2:429–31.PubMed

88.

Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. 2011;77:269–75.PubMedCentralPubMed

89.

Claassen J, Teufel J, Kalla R, Spiegel R, Strupp M. Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. J Neurol. 2013;260:668–9.PubMed

90.

Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology. 2004;62:1623–5.PubMed

91.

Strupp M, Zwergal A, Brandt T. Episodic ataxia type 2. Neurotherapeutics. 2007;4:267–73.PubMed

92.

Hazell AS. Astrocytes are a major target in thiamine deficiency and Wernicke's encephalopathy. Neurochem Int. 2009;55:129–35.PubMed

93.

Di Gangi S, Gizzo S, Patrelli TS, Saccardi C, D'Antona D, Nardelli GB. Wernicke's encephalopathy complicating hyperemesis gravidarum: from the background to the present. J Maternal Fetal Neonatal Med. 2012;25:1499–504.

94.

Spruill SC, Kuller JA. Hyperemesis gravidarum complicated by Wernicke's encephalopathy. Obstet Gynecol. 2002;99:875–7.PubMed

95.

Hung SC, Hung SH, Tarng DC, Yang WC, Chen TW, Huang TP. Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2001;38:941–7.PubMed

96.

Sullivan EV, Fama R. Wernicke's encephalopathy and Korsakoff's syndrome revisited. Neuropsychol Rev. 2012;22:69–71.PubMed

97.

Schabelman E, Kuo D. Glucose before thiamine for Wernicke encephalopathy: a literature review. J Emerg Med. 2012;42:488–94.PubMed

98.

Kumar N. Neurologic aspects of cobalamin (B12) deficiency. Handb Clin Neurol. 2014;120:915–26.PubMed

99.

Kalita J, Chandra S, Bhoi SK, Agarwal R, Misra UK, Shankar SK, Mahadevan A. Clinical, nerve conduction and nerve biopsy study in vitamin B12 deficiency neurological syndrome with a short-term follow-up. Nutri Neurosci. 2013. doi:10.1179/1476830513Y.0000000073.

100.

Briani C, Dalla Torre C, Citton V, Manara R, Pompanin S, Binotto G, et al. Cobalamin deficiency: clinical picture and radiological findings. Nutrients. 2013;5:4521–39.PubMedCentralPubMed

101.

Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368:2041–2.PubMed

102.

Reynolds EH. The neurology of folic acid deficiency. Handb Clin Neurol. 2014;120:927–43.PubMed

103.

Pfeiffer RF. Neurologic manifestations of malabsorption syndromes. Handb Clin Neurol. 2014;120:621–32.PubMed

104.

Becker DA, Balcer LJ, Galetta SL. The neurological complications of nutritional deficiency following bariatric surgery. J Obes. 2012;2012:608534.PubMedCentralPubMed

105.

Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol. 2010;257:869–81.PubMedCentralPubMed

106.

Pineles SL, Wilson CA, Balcer LJ, Slater R, Galetta SL. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol. 2010;55:386–92.PubMed

107.

Kumar N. Neurologic presentations of nutritional deficiencies. Neurol Clin. 2010;28:107–70.PubMed

108.

Goodman BP, Bosch EP, Ross MA, Hoffman-Snyder C, Dodick DD, Smith BE. Clinical and electrodiagnostic findings in copper deficiency myeloneuropathy. J Neurol Neurosurg Psychiatry. 2009;80:524–7.PubMed

109.

Prodan CI, Rabadi M, Vincent AS, Cowan LD. Copper supplementation improves functional activities of daily living in adults with copper deficiency. J Clin Neuromuscul Dis. 2011;12:122–8.PubMed

110.

Evans-Galea MV, Pebay A,Dottori M, Corben LA, Ong SH, Lockhart PJ, Delatycki MB. Cell and gene therapy for Friedreich ataxia - progress to date. Hum Gene Ther. 2014. doi:10.1089/hum.2013.180.

Title: Therapies for Ataxias
Authors: Laurence Martineau, MD
Anne Noreau, MSc
Nicolas Dupré, MD, MSc, FRCP(C)
Publication date: 01-07-2014
Publisher: Springer US
Published in: Current Treatment Options in Neurology / Issue 7/2014
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-014-0300-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Therapies for Ataxias

Opinion statement

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content